Cancer Protein Description
This report provides a detailed description of a selected cancer protein with information collected from various sources, including UniProt, the Wellcome Trust Sanger Institute’s Catalogue of Somatic Mutations in Cancer (COSMIC), and the Atlas of Genetics and Cytogenetics in Oncology and Haematology.
| Protein Name: | BRCC3 |
| Gene Name: | BRCC3 |
| Protein Full Name: | Lys-63-specific deubiquitinase BRCC36 |
| Alias: | BRCA1/BRCA2-containing complex subunit 36; BRCA1/BRCA2-containing complex, subunit 3; BRCC36; C6.1A; CXorf53; EC 3.1.2.15; Lys-63-specific deubiquitinase BRCC36 |
| Mass (Da): | 36072 |
| Number AA: | 316 |
| UniProt ID: | P46736 |
| Locus ID: | 79184 |
| COSMIC ID: | BRCC3 |
| Gene location on chromosome: | Xq28 |
| Cancer protein type: | UNCLEAR |
| Effect of cancer mutation on protein: | UNCLEAR |
| Effect of active protein on cancer: | UNCLEAR |
| Number of cancer specimens: | 20195 |
| Percent of cancer specimens with mutations: | 0.29 |
| Normal role description: | BRCC3 is a ubiquitin E3 ligase that enhances cellular survival following DNA damage; it is responsible for the stable accumulation of BRCA1 at DNA break sites. It can specifically cleave Lys 63-linked polyubiquitin chains, and it regulates the abundance of these chains in chromatin. The loss of this gene results in abnormal angiogenesis and is associated with syndromic moyamoya. |
| Commentary on involvement of protein in cancer: | 2% (1/59) of ovary samples, 1/206 breast cancer samples and 1% (1/146) of lung cancer samples also contained mutations (Sanger COMSIC) |